Evidence map›Paper›PMID 40627103›Full record

ArticleAnnals of surgical oncology2025

Outcomes After Neoadjuvant Targeted Therapy in Patients with ALK or ROS1 Rearrangement Locally Advanced Non-small Cell Lung Cancer.

Zhao An, Xiaodong Yang, Yuming Zhu, Deping Zhao, Chang Chen, Chenyang Dai

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhao An *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Xiaodong Yang *Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Yuming ZhuDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Deping ZhaoDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Chang ChenDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Chenyang DaiDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. daichenyang@tongji.edu.cn.

Funding

Clinical Research Plan of SHDC SHDC2020CR4028Incubation Project of Shanghai Pulmonary Hospital fkzr2109National Natural Science Foundation of China 81900421National Natural Science Foundation of China 82203635Shanghai Sailing Program 21YF1438600the project from the Science and Technology Commission of Shanghai Municipality 23ZR1453200the Shanghai Rising Star Program 20QA1408300"Youth Cultivation" Project of Shanghai Pulmonary Hospital Fkxr2303
6 · The paper itself

Abstract

backgroundThis study was designed to investigate the outcomes after neoadjuvant targeted therapy in patients with anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 (ROS1) rearrangement locally advanced non-small cell lung cancer (NSCLC) in the real world.

methodsPatients with ALK or ROS1 rearrangement locally advanced NSCLC received neoadjuvant targeted therapy between October 2018 and December 2023 in Shanghai pulmonary hospital were enrolled in this study. Perioperative and follow-up data of these patients were retrospectively recorded.

resultsThirty-eight patients were enrolled in this study. ALK and ROS1 rearrangement were confirmed in 32 (84.2%) and 6 (15.8%) patients respectively. Neoadjuvant targeted therapy was performed a mean of 4.1 ± 3.4 months. Patients with yc IA disease had significant tumor shrinkage compared with the others (-51.4 ± 16% vs. -41.7 ± 16.6 %, P ≤ 0.05). All patients had R0 resection. Pathological complete response and major pathological response were observed in 12 (31.6%) and 13 (34.2%) patients respectively. The mean overall survival time was 23.5 ± 13.5 months, and the mean disease-free survival (DFS) time was 19.2 ± 9.4 months. Kaplan-Meier analysis showed patients with histologic grade 3 had worse DFS compared with the others. Univariate and multivariable Cox regression analyses showed histologic grade 3 was an independent risk factor of DFS.

conclusionsResults of this study preliminary showed the safety and feasibility of surgery after neoadjuvant targeted therapy in some locally advanced NSCLC patients with ALK or ROS1 mutation. Histologic grade 3 was an independent risk factor of DFS for these patients.

Indexed as

Anaplastic Lymphoma KinaseCarcinoma, Non-Small-Cell LungGene RearrangementLung NeoplasmsMolecular Targeted TherapyNeoadjuvant TherapyProtein-Tyrosine KinasesProto-Oncogene ProteinsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisALK protein, humanAnaplastic Lymphoma KinaseMAS1 protein, humanProtein-Tyrosine KinasesProto-Oncogene MasProto-Oncogene ProteinsROS1 protein, humanALKNeoadjuvant targeted therapyNon-small cell lung cancerROS1Surgery

Identifiers

PMID40627103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.